Positive results from a study of ivacaftor (Kalydeco®) in children ages 1 to 2 were announced today.
Site Search
Showing 1 - 10 of 46 results
News
|
May 6, 2011
|
1 min read
News
|
Nov. 8, 2011
|
2 min read
News
|
March 4, 2011
|
2 min read
News
|
Oct. 25, 2011
|
2 min read
News
|
Dec. 7, 2017
|
2 min read
Two Phase 3 clinical trials of tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) showed positive results, Vertex Pharmaceuticals announced today.
News
|
March 28, 2017
|
4 min read
New data show positive results in individuals with a single F508del mutation as well as people with two copies of F508del and support continued development of triple combination therapies.
News
|
July 18, 2017
|
6 min read
The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.
News
|
Nov. 17, 2010
|
3 min read
News
|
July 15, 2008
|
1 min read
News
|
Sept. 16, 2008
|
1 min read